Skip to main content
OpenTrials

Clinical trial condition

Angioimmunoblastic T-cell Lymphoma

Explore clinical trials studying Angioimmunoblastic T-cell Lymphoma. Study availability and eligibility vary by location and protocol.

70 public trials 5 recruiting studies
Refine in advanced search Browse all conditions

Angioimmunoblastic T-cell Lymphoma trial results

Recruiting

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

NCT04803201

Conditions
Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Follicular T-Cell Lymphoma, +16 more
Locations
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • Cedars-Sinai Medical Center Los Angeles, California, United States
View all 96 locations
View Trial Details
Recruiting

A Registry for People With T-cell Lymphoma

NCT05978141

Conditions
Adult T-Cell Leukemia/Lymphoma, Aggressive NK-cell Leukemia, Anaplastic Large Cell Lymphoma, ALK-Positive, +54 more
Locations
  • City of Hope Cancer Center (Data collection only) Duarte, California, United States
  • UNIVERSITY OF CALIFORNIA SAN DIEGO (Data collection only) San Diego, California, United States
  • University of California San Francisco (Data collection only) San Francisco, California, United States
  • Stanford University Medical Center (Data collection only) Stanford, California, United States
View all 26 locations
View Trial Details
Recruiting

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

NCT06561048

Conditions
Angioimmunoblastic T-cell Lymphoma, Follicular T-Cell Lymphoma, Hemic and Lymphatic Diseases, +16 more
Locations
  • City of Hope National Medical Center Duarte, California, United States
  • University of California, Irvine Irvine, California, United States
  • University of California San Francisco San Francisco, California, United States
  • Yale University New Haven, Connecticut, United States
View all 34 locations
View Trial Details
Recruiting

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

NCT04234048

Conditions
Angioimmunoblastic T-cell Lymphoma, Cutaneous T-Cell Lymphoma, Cutaneous T-Cell Lymphoma, Unspecified, +23 more
Locations
  • Mayo Clinic Arizona Scottsdale, Arizona, United States
  • City of Hope Medical Foundation Duarte, California, United States
  • University of Southern California Los Angeles, California, United States
  • University of Colorado Anschutz Medical Campus Aurora, Colorado, United States
View Trial Details
Active, not recruiting

Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency

NCT01787409

Conditions
Aggressive Non-Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, +40 more
Locations
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Emory University/Winship Cancer Institute Atlanta, Georgia, United States
  • University of Iowa/Holden Comprehensive Cancer Center Iowa City, Iowa, United States
  • Mayo Clinic Rochester, Minnesota, United States
View Trial Details
Active, not recruiting

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma

NCT03113500

Conditions
Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Positive, Anaplastic Large Cell Lymphoma, ALK-negative, +26 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • Hackensack University Medical Center Hackensack, New Jersey, United States
  • Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
  • M D Anderson Cancer Center Houston, Texas, United States
View Trial Details
Completed

Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma

NCT02232516

Conditions
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, +32 more
Locations
  • City of Hope Duarte, California, United States
  • Yale University New Haven, Connecticut, United States
  • Northwestern University Chicago, Illinois, United States
  • Weill Cornell Medicine New York, United States
View Trial Details
Completed

A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)

NCT02588651

Conditions
Adult T-Cell Leukemia/Lymphoma, Angioimmunoblastic T-cell Lymphoma, Enteropathy Associated T-cell Lymphoma, +22 more
Locations
  • Wayne State University, Karmanos Cancer Institute Detroit, Michigan, United States
  • Hackensack University Medical Center Hackensack, New Jersey, United States
  • University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center Cleveland, Ohio, United States
  • Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center Cleveland, Ohio, United States
View Trial Details

Related conditions